Relmada Therapeutics, Inc. reported $5.2M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.2M (to Q4 2023). Net income: −$62M, trailing twelve months to Q2 2026. EPS: −$0.92, trailing twelve months to Q2 2026.

RLMDRelmada Therapeutics, Inc.

Healthcare

$3.16+59% 1Y

$3.16

$1.9352 weeks$7.86

RLMD as reported

Relmada Therapeutics, Inc. reported $5.2M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$5.2M

Revenue, trailing twelve months · to Q4 2023 · every figure below is as filed, with no scoring applied

Net income: −$62M
Net income · −8.7% year on year · trailing twelve months to Q2 2026
EPS: −$0.92
EPS · −59% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RLMD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.2M	n/a	Q4 2023 · 10 quarters behind
Net income	−$62M	−8.7%	Q2 2026
EPS	−$0.92	−59%	Q2 2026
Operating margin	−2022%	n/a	Q4 2023 · 10 quarters behind
Net margin	−1925%	n/a	Q4 2023 · 10 quarters behind
ROE	−179%	n/a	Q2 2026
ROA	−123%	n/a	Q2 2026
ROIC	964%	n/a	Q2 2019 · 28 quarters behind
Free cash flow	−$6.0M	n/a	Q4 2017 · 34 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.